World’s first PROM for RSV trials – the RiiQ™

This recently published paper describes Janssen Pharmaceutica’s hospitalized acute respiratory tract infection (HARTI) study which used MESH’s Respiratory Intensity and Impact Questionnaire (RiiQ™) Symptom Scale, derived from the flu-iiQ™, to assess and compare the burden of respiratory infection symptoms for patients with influenza, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV) infection, with or without core risk factors (CRF).

Falsey A, Walsh E, Osborne RH, Vanderdijck Y, Ren X, Witek J, Kang D, Chan E, Scott J, Ispas G. Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post-discharge assessed by Respiratory Intensity and Impact Questionnaire. Influenza and Other Respiratory Viruses 11 August 2021